Navigation Links
ADVENTRX Reports Third Quarter 2012 Financial Results
Date:11/5/2012

SAN DIEGO, Nov. 5, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reported financial results for the quarter ended September 30, 2012.

"With a strong cash position of approximately $40 million, we are well positioned to start our phase 3 study of ANX-188 in sickle cell disease," stated Brian M. Culley, Chief Executive Officer of ADVENTRX.  "We are pleased that we have finalized the protocol and completed the majority of our manufacturing activities that will enable us to start the study by the end of 2012," Mr. Culley continued. 

Third Quarter 2012 Operating ResultsADVENTRX's net loss for the third quarter of 2012 was $3.2 million, or $0.07 per share (basic and diluted), compared to a net loss of $3.5 million, or $0.13 per share (basic and diluted), for the same period in 2011.

Research and development (R&D) expenses for the third quarter of 2012 were $1.7 million, a decrease of $0.4 million, or 19%, compared to $2.1 million for the same period in 2011. The net decrease was primarily due to a $0.8 million decrease in external nonclinical study fees and expenses, which was offset by increases of $0.3 million in personnel costs and $0.1 million in external clinical study fees and expenses. The decrease in external nonclinical study fees and expenses resulted primarily from decreases in research-related manufacturing expenses of $1.1 million for ExelbineTM and $0.2 million for ANX-514.  The increase in personnel costs was primarily related to increased headcount, including relocation and recruitment costs for our new Chief Medical Officer.

Selling, general and administrative (SG&A) expenses for the third quarter of 2012 were $1.8 million, a decrease of $0.2 million, or 8%, compared to $2.0 million for the same period in 2011. The decrease resulted primarily from a decrease in consulting fees and legal expenses due to cost-savings realized by discontinuation of commercial-rea
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
2. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
3. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
4. ADVENTRX Announces Appointment Of Chief Medical Officer
5. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
6. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
7. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
8. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
9. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
10. Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance
11. InspireMD Reports Results For Period Ending Sept. 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Aileron Therapeutics, Inc. ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - ... of the Aileron Therapeutics, Inc.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Aileron ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds that ... Australia , China , ... expand at a strong rate through 2023. Dental implant procedure volumes ... as patient awareness rises. Other key findings from Decision ... dental implant market: , Dental implant penetration: Penetration ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... and Company) (NYSE: BDX ), a global medical technology company,announced today that ... Credit Suisse 2007 Healthcare Conference ... (ET), Lazard Capital ... November 27, 2007 - 9:00 a.m. (ET) A live webcast ...
... Golimumab Achieved Primary and Major Secondary Endpoints in ... Trial Completed to Date in Psoriatic Arthritis, ... arthritis,receiving monthly subcutaneous (SC) injections of golimumab (CNTO ... and skin,manifestations of the disease, according to findings ...
Cached Medicine Technology:Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 2Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 3Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 4Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 5Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 6Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 7Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis 8
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... October 01, 2014 Beverly Hills licensed ... Mojas is celebrating 20 years of private practice in ... of people to achieve greater joy and fulfillment in ... of warning signs and suggestions for anyone who suspects ... explains: “Believe it or not, it’s not always ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 NoteSwift Inc., ... EHR versions 10.0, 12.1 and 13.0. NoteSwift is the ... as commands to navigate and document clinical information at ... provider spends creating a patient note by more than ... of the major pain points providers state impedes EHR ...
(Date:10/1/2014)... in Bahir Dar, Ethiopia, at the occasion of ... gathered some 150 African and international leishmaniasis experts, ... safety and efficacy monitoring plan, carried out ... Sudan, Uganda, and Ethiopia, were presented to key ... to treatment of kala-azar with the combination of ...
(Date:10/1/2014)... 01, 2014 Dr. Saj Jivraj, one ... prosthodontists, is traveling to Chennai, India, tomorrow to speak ... 2 and 3. , Dr. Jivraj is founder of ... Oxnard, Calif., and one of the world’s foremost prosthodontists, ... replacement. He is speaking to the Indian Society of ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... directs the University of Southern California Center for ... to evaluate robots as exercise coaches for adults of ... The effort, entitled "Robot Motivator: Towards Adaptive Health ... of virtual social characters on people,s motivation to exercise. ...
... , , - ... 41% from 31% in Q3 2008 , - Q3 2009 Operating ... 2009 Pre-tax Income Increases 168% from same period in 2008 , ... LWAY ), makers of the nutritious, probiotic dairy beverage called kefir, ...
... of this group with better preventive care, , THURSDAY, Nov. ... health measures can prolong lives, but only 25 percent of ... getting these recommended screenings, a new report shows. , Prepared ... and the American Medical Association, the report also lays out ...
... no more likely to have post-operative complications than those ... uterine fibroids, according to a study at Henry Ford ... fibroids, leaving the uterus intact and preserving the ability ... obese patient can present difficulties for the most experienced ...
... ... in Buffalo, NY, launched their revitalized and interactive website Monday, November 16, 2009. The ... . The project was initiated to provide users with an enhanced shopping and ordering ... (PRWEB) November 18, ...
... MELVILLE, N.Y., Nov. 19 Long Island IVF, a full ... patients achieve successful pregnancies, is now offering a new program ... treatment. Through this program and a partnership with In Vitro ... amount of money couples pay for their comprehensive treatment plans ...
Cached Medicine News:Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 2Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 3Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 4Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 5Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 6Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 7Health News:Lifeway Foods Reports Record 3rd Quarter 2009 Revenues and Earnings Results 8Health News: Too Few Older Adults Get Recommended Screenings 2Health News: Too Few Older Adults Get Recommended Screenings 3Health News:Patient's weight not linked to success of fibroid surgery 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 3Health News:Long Island IVF to Offer IVF Financial Share Program, Limiting Costs and Providing Refunds if IVF is Not Successful 2
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
Intended for the quantitative determination of magnesium in serum. Wavelength: 340 nm. Linearity: 9.7 mg/dL (4 mmol/L). Two vials, dry powder reagents....
Medicine Products: